Mikecz K
Department of Orthopedic Surgery, Rush-Presbyterian-St Luke's Medical Center, 1653 West Congress Parkway, Chicago, IL 60612-3833, USA.
Curr Opin Investig Drugs. 2000 Oct;1(2):199-203.
Vitaxin is a humanized version of LM-609 (an mAb licensed from the Scripps Research Institute and Dr David Cheresh in May 1994, which blocks the integrin receptor, alpha v beta 3) [172038]. It is in phase II trials for the potential treatment of leiomyosarcoma [316471] and is also being studied in phase I trials as an anti-inflammatory and potential rheumatoid arthritis therapy [364031,313665]. Vitaxin and non-peptides are under evaluation for use in the treatment of other diseases in which vitronectin is reputed to play a role, e.g., arthritis, psoriasis and other inflammatory diseases. Patent positions are being established on these and other applications, as well as on the structure and use of the non-RGD proteins [182507].
Vitaxin是LM - 609的人源化版本（一种1994年5月从斯克里普斯研究所和大卫·切雷什博士处获得许可的单克隆抗体，可阻断整合素受体αvβ3）[172038]。它正处于治疗平滑肌肉瘤的II期试验阶段[316471]，并且也正在I期试验中作为抗炎和潜在的类风湿性关节炎疗法进行研究[364031,313665]。Vitaxin和非肽类正在评估用于治疗其他据信玻连蛋白起作用的疾病，例如关节炎、牛皮癣和其他炎症性疾病。正在就这些及其他应用以及非RGD蛋白的结构和用途确立专利地位[182507]。
